Compare HIT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIT | RLYB |
|---|---|---|
| Founded | 1964 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 86.6M |
| IPO Year | 2024 | 2021 |
| Metric | HIT | RLYB |
|---|---|---|
| Price | $1.00 | $16.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 67.6K | 20.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $33,327,511.00 | $858,000.00 |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $69.63 | N/A |
| P/E Ratio | ★ N/A | $2.76 |
| Revenue Growth | ★ 70.99 | 43.00 |
| 52 Week Low | $0.85 | $0.48 |
| 52 Week High | $4.01 | $17.57 |
| Indicator | HIT | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 54.07 |
| Support Level | $0.99 | $15.68 |
| Resistance Level | $1.16 | $17.34 |
| Average True Range (ATR) | 0.06 | 0.48 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 10.10 | 49.33 |
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.